Literature DB >> 31690383

Asthma and allergies in pregnancy.

Jason H Kwah, Whitney W Stevens.   

Abstract

Asthma is the most common respiratory disease observed in pregnancy and is estimated to occur in approximately 5-8% of pregnant women. The course of asthma during gestation may be affected by normal physiologic changes associated with the pregnancy, environmental exposures, and adherence to medical therapy. Uncontrolled asthma poses serious risks not only to the mother but also to the fetus. However, if asthma is controlled, then most women have outcomes at or near that of the general population. Appropriate management of asthma during pregnancy includes evaluation of symptoms, regular monitoring of pulmonary function, and patient education with regard to the risks and benefits of medications. Overall, the advantages of treating asthma in pregnancy markedly outweigh any potential risks of standard medical therapies. Comorbid conditions, including allergic rhinitis or vasomotor rhinitis of pregnancy, should also be managed during pregnancy.

Entities:  

Mesh:

Year:  2019        PMID: 31690383      PMCID: PMC8242985          DOI: 10.2500/aap.2019.40.4260

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  9 in total

1.  Allergen immunotherapy: a practice parameter third update.

Authors:  Linda Cox; Harold Nelson; Richard Lockey; Christopher Calabria; Thomas Chacko; Ira Finegold; Michael Nelson; Richard Weber; David I Bernstein; Joann Blessing-Moore; David A Khan; David M Lang; Richard A Nicklas; John Oppenheimer; Jay M Portnoy; Christopher Randolph; Diane E Schuller; Sheldon L Spector; Stephen Tilles; Dana Wallace
Journal:  J Allergy Clin Immunol       Date:  2010-12-03       Impact factor: 10.793

Review 2.  NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update.

Authors: 
Journal:  J Allergy Clin Immunol       Date:  2005-01       Impact factor: 10.793

Review 3.  Respiratory physiologic changes in pregnancy.

Authors:  Robert A Wise; Albert J Polito; Vidya Krishnan
Journal:  Immunol Allergy Clin North Am       Date:  2006-02       Impact factor: 3.479

4.  Relative perinatal safety of salmeterol vs formoterol and fluticasone vs budesonide use during pregnancy.

Authors:  Benoit Cossette; Marie-France Beauchesne; Amélie Forget; Catherine Lemière; Pierre Larivée; Evelyne Rey; Lucie Blais
Journal:  Ann Allergy Asthma Immunol       Date:  2014-03-19       Impact factor: 6.347

Review 5.  Nasal polyps and rhinosinusitis.

Authors:  Jason H Kwah; Anju T Peters
Journal:  Allergy Asthma Proc       Date:  2019-11-01       Impact factor: 2.587

Review 6.  Current Evidence on Safety and Practical Considerations for Administration of Sublingual Allergen Immunotherapy (SLIT) in the United States.

Authors:  Tolly G Epstein; Christopher Calabria; Linda S Cox; Sten Dreborg
Journal:  J Allergy Clin Immunol Pract       Date:  2016-11-01

7.  The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy.

Authors:  Jennifer Namazy; Michael D Cabana; Angela E Scheuerle; John M Thorp; Hubert Chen; Gillis Carrigan; Yan Wang; Joachim Veith; Elizabeth B Andrews
Journal:  J Allergy Clin Immunol       Date:  2014-10-19       Impact factor: 10.793

Review 8.  Asthma Outcomes and Management During Pregnancy.

Authors:  Catherine A Bonham; Karen C Patterson; Mary E Strek
Journal:  Chest       Date:  2017-09-01       Impact factor: 9.410

Review 9.  The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis.

Authors:  Simerpal K Gill; Lisa O'Brien; Thomas R Einarson; Gideon Koren
Journal:  Am J Gastroenterol       Date:  2009-04-28       Impact factor: 10.864

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.